CLDN News Alert Celladon Corp (CLDN) 17.76 12/16/2014 22:43:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celladon Corp (CLDN) 17.76 $CLDN

Celladon Corporation Added to NASDAQ Biotechnology Index
GlobeNewswire - Tue Dec 16, 7:06AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has been added to the NASDAQ Biotechnology Index, through the annual update that will become effective prior to market open on Monday, December 22, 2014.
CLDN: 17.76 (+0.03)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), FPRX: 21.92 (+0.07), ZFGN: 21.67 (-0.08), CRIS: 1.15 (-0.01), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), ZGNX: 1.11 (-0.03), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), NDAQ: 45.74 (-0.72), FPRX: 21.92 (+0.07), CRIS: 1.15 (-0.01), ZFGN: 21.67 (-0.08), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:09AM CST
Celladon Corporation stock fell nearly 9% last trading session, reversing its recent trend
BIIB: 325.13 (-10.67), ANIP: 55.08 (+1.32), CLDN: 17.76 (+0.03), AFFX: 8.90 (+0.10)

Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
UIHC: 20.28 (+0.25), CLDN: 17.76 (+0.03), BRID: 7.54 (+0.04), HCCI: 10.44 (+0.35), MIND: 5.82 (+0.13), ROSE: 18.39 (+1.18), OBAS: 6.96 (-0.06), MEIP: 3.95 (-0.12), IESC: 7.33 (+0.42), SRPT: 12.60 (-0.40), CONN: 14.15 (-1.63), LINE: 12.54 (+2.71), DGLY: 14.38 (+0.34)

Nasdaq stocks posting largest volume increases
AP - Thu Dec 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
SOFO: 7.69 (+0.25), CLNT: 3.43 (-0.16), WATT: 7.35 (-0.10), MLVF: 12.08 (+0.28), RNST: 28.17 (-0.22), CLDN: 17.76 (+0.03), CYRN: 1.58 (-0.11), AIRT: 26.78 (+0.01), CNTY: 4.99 (-0.05)

Celladon Corp. (CLDN) Jumps: Stock Adds 14.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 7:51AM CST
Celladon Corporation (CLDN) was a big mover last session, as its shares rose almost 15% on the day.
ANIP: 55.08 (+1.32), ILMN: 175.18 (-3.13), CLDN: 17.76 (+0.03), AFFX: 8.90 (+0.10)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:45AM CST

BLUE: 85.87 (-0.33), SC: 17.76 (+0.04), ANV: 0.85 (+0.07), UTIW: 10.74 (-0.06), AKAO: 11.97 (+0.05), CLDN: 17.76 (+0.03), MZOR: 14.12 (-0.49), NBG: 1.80 (-0.03), TTI: 5.44 (+0.42), TPLM: 4.57 (+0.59), CGIX: 6.29 (+0.12), LCI: 42.70 (-1.35), SAVE: 68.70 (+0.11), PQ: 3.25 (-0.01), AFMD: 5.43 (-0.25), ENSV: 1.44 (-0.02), CTC: 0.64 (-0.01), CONN: 14.15 (-1.63), PDCE: 34.04 (+2.10), KPTI: 31.07 (-0.82)

Celladon Corporation to Present at 11th Global Cardio Vascular Clinical Trial Forum
GlobeNewswire - Mon Dec 01, 3:13PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Janice Pogoda, Ph.D., Executive Director of Biostatistics at Celladon, has been selected to present guidance for future clinical trials of therapies for cardiac disease during the 11 Global Cardio Vascular Clinical Trial Forum (CVCT). The presentation will take place during Session 1: The Specific Framework of Cell and Gene Therapy Trials, on Saturday, December 6, 2014 from 11:30 a.m. - 3:00 p.m. EST in Washington D.C.
CLDN: 17.76 (+0.03)

Celladon Selected to Present During the "Best of Circulation Research" Symposium at the American Heart Association Scientific Sessions 2014
GlobeNewswire - Fri Nov 14, 7:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer of Celladon, was selected to present three-year long-term follow up data of MYDICAR in patients with advanced heart failure during the "Best of Circulation Research" Symposium at the American Heart Association (AHA) Scientific Sessions 2014 on Sunday, November 16, 2014 in Chicago.
CLDN: 17.76 (+0.03)

Celladon Net loss of $8.35M
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:18AM CST

CLDN: 17.76 (+0.03)

Celladon Reports Third Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Nov 12, 5:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced financial results for the quarter ended September 30, 2014 and recent corporate highlights and updates.
CLDN: 17.76 (+0.03)

Celladon Corporation to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Fri Nov 07, 3:05PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 17.76 (+0.03)

Celladon Corporation to Present at Credit Suisse Healthcare Investor Conference
GlobeNewswire - Wed Nov 05, 3:38PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 17.76 (+0.03)

Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for MYDICAR(R)
GlobeNewswire - Mon Nov 03, 5:00AM CST
-- Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR(R)
CLDN: 17.76 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fall Pest Risks Linger as Mild Weather Extends Threat

Updated Category News Views 64

A cold snap is not a magic off switch for mosquitoes, ticks, or rodents, and that is the sober point behind the National Pest Management Association's fall and winter 2026 Public Health Pest Index. The group is flagging conditions, not predicting that every household in a named city will face an infestation or illness. Still, mild temperatures, rain, flooding, and plenty...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 96

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 48

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 222

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 104

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 98

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 98

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
Lithium's Next Leg Depends on Storage, Not EV Hype

Updated Category News Views 136

Grid batteries are quietly becoming lithium’s second engine, and that matters more than another flashy electric-vehicle sales headline. The market is projected to rise from $40.87 billion in 2026 to $57.77 billion by 2031, a 7.2% compound annual growth rate. Respectable growth, certainly. But this is not a straight line, and anybody treating a five-year market forecast...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 30

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 126

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Scaling New Heights: S&P 500's Path to 6,500

Updated Category News Views 260

Market Rally Highlights The financial markets witnessed an impressive surge recently, with significant recoveries noted in leading indexes. The S&P 500, a crucial gauge for large-cap stocks, notably rose by 10.6% during the second quarter of the year. Many factors contributed to this remarkable increase, underscoring investor confidence despite some ongoing challenges in...

Continue Reading
Pultruded Spar Cap Market Growth: Forecasting US$ 2.1 Billion

Updated Category News Views 194

Insights into the Pultruded Spar Cap Market and Future Growth The Pultruded Spar Cap Market is on the cusp of significant expansion, with projections suggesting a robust annual growth rate of 16.7% from 2024 through 2030. Industry analyses indicate that this favorable trend could lead to a market size of US$ 2.1 billion by the end of the projection period. This report is...

Continue Reading
Irritable Bowel Syndrome Treatment Growth Projections 2033

Updated Category News Views 107

Irritable Bowel Syndrome: An Overview Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that can significantly affect a person's quality of life, leading to a range of uncomfortable symptoms such as abdominal discomfort, bloating, and irregular bowel movements. With various subtypes like IBS with Diarrhea (IBS-D) and IBS with Constipation (IBS-C), it...

Continue Reading
Anoto Group Reports Second Quarter Results 2024

Updated Category News Views 242

Overview of the Interim Report for 2024 The interim report covering January to June 2024 provides important insights into Anoto Group AB's operations and financial health. Anoto Group continues to be a leader in technology, particularly in optical recognition and digital writing. This report emphasizes key financial metrics and the company's strategic initiatives in a...

Continue Reading
Mission Critical Group Welcomes Mark Feasel as VP of Sales

Updated Category News Views 276

Mission Critical Group Appoints New Vice President of Sales Mission Critical Group (MCG), a leader in critical power infrastructure solutions, is excited to announce the appointment of industry veteran Mark Feasel as the Vice President of Sales in the Commercial and Innovation Division. With this strategic addition, MCG aims to enhance its sales strategy and broaden its...

Continue Reading